In our case, haematoxylin and eosin and orcein staining as well as immunostaining with anti-BMP2, CD31, CD68, CD63 and Alix antibodies yielded valuable information about CAVD progression at the tissue level. The gene discussed is BMP2; the disease is congenital bilateral aplasia of vas deferens from CFTR mutation.